Adicet Bio, Inc. SEC filings ACET
Adicet Bio, Inc. has 682 filings in SEC EDGAR's recent list, going back to Oct 27, 2017. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 26.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Mar 23, 2026 | — |
| CORRESP | Letter to the SEC | Mar 19, 2026 | — |
| UPLOAD | Letter from the SEC | Mar 18, 2026 | — |
| EFFECT | Filing | Mar 14, 2025 | — |
| CORRESP | Letter to the SEC | Mar 12, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 11, 2025 | — |
| DEFR14A | Filing | Apr 26, 2024 | — |
| EFFECT | Filing | May 9, 2022 | — |
| CORRESP | Letter to the SEC | May 5, 2022 | — |
| UPLOAD | Letter from the SEC | Mar 16, 2022 | — |
| EFFECT | Filing | May 21, 2021 | — |
| CORRESP | Letter to the SEC | May 19, 2021 | — |
| UPLOAD | Letter from the SEC | May 18, 2021 | — |
| EFFECT | Filing | Mar 30, 2021 | — |
| CORRESP | Letter to the SEC | Mar 26, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 18, 2021 | — |
| EFFECT | Filing | Aug 20, 2020 | — |
| CORRESP | Letter to the SEC | Aug 19, 2020 | — |
| CORRESP | Letter to the SEC | Aug 12, 2020 | — |
| UPLOAD | Letter from the SEC | Aug 6, 2020 | — |
| 425 | Filing | Aug 5, 2020 | — |
| CORRESP | Letter to the SEC | Jul 29, 2020 | — |
| 425 | 8-k | Jul 28, 2020 | — |
| UPLOAD | Letter from the SEC | Jul 21, 2020 | — |
| 425 | 8-k | Jun 23, 2020 | — |
| 425 | 8-k | Jun 2, 2020 | — |
| 425 | 8-k | Apr 29, 2020 | — |
| EFFECT | Filing | Feb 12, 2019 | — |
| UPLOAD | Letter from the SEC | Feb 11, 2019 | — |
| CORRESP | Letter to the SEC | Feb 8, 2019 | — |
| CERT | Filing | Jan 25, 2018 | — |
| EFFECT | Filing | Jan 25, 2018 | — |
| CT ORDER | Filing | Jan 25, 2018 | — |
| CORRESP | Letter to the SEC | Jan 23, 2018 | — |
| CORRESP | Letter to the SEC | Jan 23, 2018 | — |
| 8-A12B | Filing | Jan 22, 2018 | — |
| CORRESP | Letter to the SEC | Jan 5, 2018 | — |
| DRSLTR | Filing | Dec 22, 2017 | — |
| DRS/A | Filing | Dec 22, 2017 | — |
| UPLOAD | Letter from the SEC | Dec 18, 2017 | — |
| DRSLTR | Filing | Dec 1, 2017 | — |
| DRS/A | Filing | Dec 1, 2017 | — |
| UPLOAD | Letter from the SEC | Nov 22, 2017 | — |
| DRS | Filing | Oct 27, 2017 | — |
Showing 44 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ACET (Nasdaq)
- Fiscal year ends
- December 26
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1720580
- Former names
- resTORbio, Inc. (until Aug 21, 2020)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.